IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY
CIV-2013-485-3115 [2013] NZHC 3203
UNDER the Trade Marks Act 2002
IN THE MATTER of an appeal from the decision of the Assistant Commissioner of Trade Marks dated 1 July 2013
ANDTrade Marks Appplication Nos 812734 and 812736
BETWEEN BAYER CONSUMER CARE AG Appellant
ANDDBC, LLC Respondent
Hearing: 18 November 2013
Counsel: H Cull QC and A J Evans for Appellant
Respondent abides decision of the Court
Judgment: 3 December 2013
JUDGMENT OF GODDARD J
This judgment was delivered by me on 3 December 2013 at 3.30 pm, pursuant to r 11.5 of the High Court Rules.
Registrar/Deputy Registrar
Solicitors:
Henry Hughes and Co, Wellington for Appellant
BAYER CONSUMER CARE AG v DBC, LLC [2013] NZHC 3203 [3 December 2013]
[1] This is an appeal from the decision of the Assistant Commissioner of Trademarks (the Commissioner) dated 1 July 2013 allowing the registration of the respondent’s trade mark in two applications:
(i) No 812734 (ii) No 812736
[2] The appellant is Bayer Consumer Care AG, a division of Bayer Healthcare, a
subgroup of Bayer AG. The appellant has a presence in more than 100 countries with a portfolio of more than 170 consumer healthcare products.
[3] The respondent is a direct sales company which began business operations in
2002. The respondent’s goods are sold through independent distributors in various
countries including in New Zealand.
[4] The appellant seeks by way of relief orders reversing the Commissioner’s decision and, in the exercise of the powers that could have been exercised by the Commissioner, declining registration of the respondent’s trade marks numbers
812734 and 812736, and costs.
[5] The respondent advised that it does not wish to be heard on the appeal and will abide the decision of the Court.
The ELEVIT product
[6] Two products lie at the centre of this case. The first relates to the ELEVIT product, a vitamin and mineral supplement especially created for women who are pregnant, planning to become pregnant or are breastfeeding. ELEVIT is marketed and sold under the trade mark ELEVIT. The mark was first registered in 1966 and is now registered in 145 countries.
[7] The mark was registered in New Zealand on 17 March 1972 and is deemed to have been registered here since 1969 (when registration was first applied for).
Registration encompasses the word ELEVIT and covers “vitamin preparations” in
class 5.
[8] The ELEVIT product was first launched in 1984 and its market worldwide is significant. It is an over-the-counter product, sold in blister packs in quantities of 30 or 100 tablets, and is available from pharmacies without prescription. The product was approved as a registered medicine in New Zealand in 2001 and has been sold in New Zealand since 2002. It is sold in 100 per cent of all Unichem, Amcal, Life and Radius pharmacies in New Zealand.
[9] The evidence before the Court establishes that, internationally and in New Zealand, sales of and promotional expenditure for the ELEVIT product have…
Keep reading for free
Create a free CaseChat account to read Bayer Consumer Care AG v DBC, LLC and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] NZHC 3203
- Decision Date
CaseChat Overview and Summary
The central issue in this case is whether the marks ELEVIT and ELEVIV are sufficiently similar to cause confusion among consumers. The Commissioner had found that the marks were not similar enough to cause confusion, despite their significant visual and phonetic resemblance. The appellant argued that the Commissioner erred in her assessment of similarity and failed to consider the potential for deception and confusion among consumers. Goddard J found that the Commissioner had indeed erred in her assessment, noting that the visual, phonetic, and stylistic similarities between the marks, along with the similarity in the nature of the products, created a real risk of consumer confusion and deception. The Court also found that the Commissioner had failed to properly apply the totality test and had not considered the impact of the last letter of each mark, which is generally of lesser importance than the first part of the mark.
Furthermore, Goddard J held that the Commissioner had erred by not considering whether the use of the respondent’s marks would amount to passing off and/or a breach of the Fair Trading Act 1986. The Court found that the similarity between the marks was such that it amounted to misrepresentation, leading to potential consumer deception. The Court also determined that the Commissioner had misapplied the similarity test when considering the conflict with the registered mark ELEVIT.
The appeal was allowed, and the Court reversed the Commissioner’s decision. The registration of the respondent’s trade marks No 812734 and No 812736 was declined, and costs were awarded to the appellant on a 2B basis. This decision underscores the importance of a comprehensive assessment of similarity and the potential for consumer confusion when considering trade mark applications.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.